How further suppression of virus replication could improve current HBV treatment (Q35622347)

9 August 2017

0 references

How further suppression of virus replication could improve current HBV treatment (English)

1 reference

9 August 2017

John E Tavis

1

1 reference

PubMed ID

23977931

9 August 2017

Adam J Gehring

series ordinal

2

1 reference

PubMed ID

23977931

9 August 2017

Yuan Hu

series ordinal

3

1 reference

9 August 2017

1 August 2013

1 reference

Expert Review of Anti-infective Therapy

9 August 2017

1 reference

9 August 2017

11

1 reference

9 August 2017

8

1 reference

9 August 2017

755-757

1 reference

Chronic hepatitis B: what should be the goal for new therapies?

9 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436969

The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436969

Hepatitis B virus reactivation associated with anti-neoplastic therapy.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436969

DNA prime-adenovirus boost immunization induces a vigorous and multifunctional T-cell response against hepadnaviral proteins in the mouse and woodchuck model

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436969

Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436969

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436969

Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436969

Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436969

Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436969

Hepatitis B virus resistance to nucleos(t)ide analogues.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436969

T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436969

Hepatitis B virus infection--natural history and clinical consequences

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436969

Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients

12 July 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.814846

Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.814846

A new magic bullet for chronic hepatitis B infection: is this the end of the story?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.814846

Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.814846

Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.814846

Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide Analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.814846

Hepatitis B virus as a gene delivery vector activating foreign antigenic T cell response that abrogates viral expression in mouse models

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23977931

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1586/14787210.2013.814846

1 reference

9 August 2017

1 reference

9 August 2017

1 reference

PubMed ID

23977931